TABLE 5Continued Name Dosage, mg·kg-1body weight Adverse events per system ART drug interactions Pyrazinamide 30–40 (maximum 2000 mg) TBM: 35–45 (maximum 2000 mg) Dermatological: mild to severe maculopapular rash, pruritus, severe urticaria or anaphylaxis (rare), mild transient flushing reactions (rare), mild to severe photosensitivity Systemic: hepatitis, elevated urate levels Musculoskeletal: arthritis/arthralgia Ethambutol 15– Drug-susceptible TBM: 17.5–22.5 Dermatological: mild to severe maculopapular rash, pruritus, severe urticaria or anaphylaxis (rare) Ophthalmic: severe optic neuropathy, neuritis (rare) Rifapentine Dose per weight bands as outlined in WHO guidelines depending on whether used daily or once weekly Systemic: hepatitis, discoloration of secretions, gastrointestinal disturbance Rifabutin 5– Uveitis, myelosuppression Levofloxacin 15– Sleep disturbance, gastrointestinal disturbance, arthralgia/arthritis, headache, idiopathic raised intracranial pressure Moxifloxacin 10–15 (maximum 400 mg) Sleep disturbance, gastrointestinal disturbance, arthralgia/arthritis, headache, idiopathic raised intracranial pressure, QT interval prolongation Bedaquiline Dose per weight bands as outlined in WHO guidelines Headache, nausea, liver dysfunction, QT interval prolongation, arthralgia Efavirenz: reduces the levels of bedaquiline so it is contraindicated to co-administer the two Protease inhibitors (LPV/r, ATV/r and darunavir): increase the plasma levels of bedaquiline, and can increase the risk of cardiac and hepatic toxicity it is contraindicated to co-administer Linezolid 15, once daily in children 1–15 kg 10–12, once daily in children 15 kg Diarrhoea, headache, nausea, myelosuppression, peripheral neuritis, optic neuritis, lactic acidosis, pancreatitis Continued https://doi.org/10.1183/2312508X.10025322 227 CHILDREN AND ADOLESCENTS |E. LÓPEZ-VARELA ET AL.